Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)
Compose a Response to This Article
Other responses
No responses have been published for this article.
